Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Pulmonary Arterial Hypertension Market Research Report by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog), by Distribution - Global Forecast to 2025

Published by 360iResearch LLP Product code 931127
Published Content info 126 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pulmonary Arterial Hypertension Market Research Report by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog), by Distribution - Global Forecast to 2025
Published: April 1, 2020 Content info: 126 Pages
Description

The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%.

"The Prostacyclin & Prostacyclin Analog is projected to witness the highest growth during the forecast period"

On the basis of Drug Class, the Pulmonary Arterial Hypertension Market is studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog. The Prostacyclin & Prostacyclin Analog commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Calcium Channel Blocker. On the other hand, the Prostacyclin & Prostacyclin Analog is expected to grow at the fastest CAGR during the forecast period, followed by the Calcium Channel Blocker.

"The Online Pharmacy is projected to witness the highest growth during the forecast period"

On the basis of Distribution, the Pulmonary Arterial Hypertension Market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Retail Pharmacy. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period, followed by the Retail Pharmacy.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

On the basis of Geography, the Pulmonary Arterial Hypertension Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Europe, Middle East & Africa. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period, followed by the Europe, Middle East & Africa.

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Arterial Hypertension Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Arterial Hypertension Market including Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players
  • 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
  • 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 4. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?
  • 2. What are the inhibiting factors and their impact analysis shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?
  • 3. What is the competitive position if vendors in the Global Pulmonary Arterial Hypertension Market?
  • 4. How Porters Five Forces define the Global Pulmonary Arterial Hypertension Market landscape?
  • 5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?
  • 6. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?
  • 7. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?
  • 8. What are the modes and strategic moves considered suitable for entering the Global Pulmonary Arterial Hypertension Market?
Table of Contents
Product Code: MRR-47B0AE5

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research & Forecasting

  • 2.1. Research Methodology
  • 2.2. Forecasting Methodology

3. Executive Summary

  • 3.1. Market Outlook
  • 3.2. Geography Outlook
  • 3.3. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Pulmonary Arterial Hypertension Market, By Geography
  • 4.3. Pulmonary Arterial Hypertension Market, By Drug Class
  • 4.4. Pulmonary Arterial Hypertension Market, By Distribution

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
    • 5.2.2. Supportive government initiatives for the development of orphan drugs
    • 5.2.3. Clinical drugs in pipeline for pulmonary treatment
  • 5.3. Restraints
    • 5.3.1. Limited awareness about presence of pulmonary arterial hypertension among patients
    • 5.3.2. High diagnosis & treatment cost of pulmonary disorders
  • 5.4. Opportunities
    • 5.4.1. Advance oral drugs for pulmonary arterial hypertension
    • 5.4.2. Technology advancement such as biomaker and new gene therapy for the treatment
  • 5.5. Challenges
    • 5.5.1. Complicated process of clinical approval of drugs

6. Industry Trends

  • 6.1. Porters Five Forces Analysis
    • 6.1.1. Threat of New Entrants
    • 6.1.2. Threat of Substitutes
    • 6.1.3. Bargaining Power of Customers
    • 6.1.4. Bargaining Power of Suppliers
    • 6.1.5. Industry Rivalry
  • 6.2. Client Customizations

7. Pulmonary Arterial Hypertension Market, By Drug Class

  • 7.1. Introduction
  • 7.2. Calcium Channel Blocker
  • 7.3. Endothelin Receptor Antagonists
  • 7.4. Phosphodiesterase 5
  • 7.5. Prostacyclin & Prostacyclin Analog

8. Pulmonary Arterial Hypertension Market, By Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Pulmonary Arterial Hypertension Market, By Americas

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Pulmonary Arterial Hypertension Market, By Asia-Pacific

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. South Korea
  • 10.10. Thailand

11. Pulmonary Arterial Hypertension Market, By Europe, Middle East & Africa

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Vendor Ranking Analysis
  • 12.3. Competitive Scenario
    • 12.3.1. Merger & Acquisition
    • 12.3.2. Agreement, Collaboration & Partnership
    • 12.3.3. New Product Launch & Enhancement
    • 12.3.4. Investment & Funding

13. Company Usability Profiles

  • 13.1. Arena Pharmaceuticals
  • 13.2. Bayer AG
  • 13.3. Bristol-Myers Squibb Company
  • 13.4. Gilead Sciences, Inc.
  • 13.5. GlaxoSmithKline Plc
  • 13.6. Johnson & Johnson
  • 13.7. Merck & Co. Inc.
  • 13.8. Novartis International AG
  • 13.9. Pfizer, Inc.
  • 13.10. United Therapeutics Corporation

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. Edition Details
  • 14.3. License Details
  • 14.4. Pricing Details

List of Figures

  • FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH FRAMEWORK
  • FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: FORECASTING METHODOLOGY
  • FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 5. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE
  • FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2017-2025 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
  • FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025 (USD MILLION)
  • FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY CALCIUM CHANNEL BLOCKER SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY ENDOTHELIN RECEPTOR ANTAGONISTS SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY PHOSPHODIESTERASE 5 SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY PROSTACYCLIN & PROSTACYCLIN ANALOG SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025 (USD MILLION)
  • FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY HOSPITAL PHARMACY SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY ONLINE PHARMACY SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY RETAIL PHARMACY SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  • FIGURE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: FPNV POSITIONING MATRIX

List of Tables

  • TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2017-2025 (USD MILLION)
  • TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  • TABLE 12. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 15. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 17. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 19. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 21. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 23. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 28. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 29. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 30. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 31. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 32. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 33. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 34. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 35. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 36. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 37. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 38. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 39. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 40. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 41. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 42. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 43. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 44. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 46. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 49. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 50. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 51. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 53. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 54. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 55. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 56. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 57. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 58. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 59. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 60. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 61. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 62. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 63. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 64. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 65. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 67. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 68. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 69. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  • TABLE 70. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
  • TABLE 71. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
  • TABLE 72. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
  • TABLE 73. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
  • TABLE 74. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
  • TABLE 75. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION & PARTNERSHIP
  • TABLE 76. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 77. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
  • TABLE 78. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: EDITION DETAILS
  • TABLE 79. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: LICENSE DETAILS
  • TABLE 80. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRICING DETAILS
Back to Top